General Information of Drug (ID: DMM6G5D)

Drug Name
AZD0914 Drug Info
Synonyms Zoliflodacin
Indication
Disease Entry ICD 11 Status REF
Neisseria gonorrhoeae infection 1A7Z Phase 3 [1]
Bacterial infection 1A00-1C4Z Phase 2 [2]
Cross-matching ID
PubChem CID
76685216
CAS Number
CAS 1620458-09-4
TTD Drug ID
DMM6G5D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [4]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [5]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [5]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [5]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [5]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [6]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [5]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [5]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [7]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [3]

References

1 ClinicalTrials.gov (NCT03959527) Zoliflodacin in Uncomplicated Gonorrhoea. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02257918) Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea. U.S. National Institutes of Health.
3 High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.Antimicrob Agents Chemother.2014 Sep;58(9):5585-8.
4 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.